European Biopharmaceutical Review |
 |
|
|
|
|
 |
| |
|
|
|
Editor’s Letter
EBR Editor Dr Deborah O’Neil details the history of diabetes treatments and how they have changed over the last eight decades, while also summarising the themes covered by the issue’s authors.
|
|
|
|
|
|
In Brief
Natural Intelligence Looks at AI
EBR's Industry Advisor, Emile Bellott, assesses how the biopharmaceutical industry and human health can benefit from the use of artificial intelligence.
|
|
|
|
|
Considerations for Protecting and Launching Biosimilars
Patenting Biosimilars
A streamlined process is enabling generics companies to enter the market with a biosimilar product and gain approval quicker than ever before, as explained byJennifer O’Farrell at Boult Wade Tennant.
|
|
|
|
Biosimilar Applications
The Patent Dance
Sanya Sukduang and Thomas J Sullivan at Finnegan detail how biosimilar applicants can now bypass the usual lengthy information exchange after the introduction of new biologics licensing rules.
|
|
|
|
|
|
Primary Sequence Analysis
Understanding Biosimilars
Amino acid sequencing relies on state-of-the-art technology to deliver the best possible analytics, though the mass spectrometry involved can be problematic, as discussed by Dr Richard Easton and Dr Andrew Reason at BioPharmaSpec.
|
|
|
|
Monitoring with Mass Spectrometry
Driving Discovery
EBR asked Dr Simon Cubbon at Thermo Fisher Scientific about the benefits of using a mass spectrometry-based multi-attribute method in drug development.
|
|
|
|
Probing Pathology with MALDI
Visualising Alzheimer’s
Dr Shannon Cornett at Bruker Daltonics suggests the ways in which ultra-high resolution mass
spectrometry imaging techniques can be advantageous in understanding neurological disorders.
|
|
|
|
|
|
Gene Therapy
End of the Tunnel
Dr Serge Braun at AFM-Téléthon examines the ever-changing climate of gene therapy technologies and how they are applied and outlines the limitations that they may present.
|
|
|
|
|
|
Monoclonal Antibody Innovations
Enhancing Analysis
A growing need for rapid high-throughput analysis of biotherapeutics results in the necessity of standardised chromatographic methods, as told by Dr Amy Farell,Dr Sara Carillo, and Dr Jonathan Bones at the National Institute of Bioprocessing Research and Training.
|
|
|
|
|
|
Red Biotechnology
Endonuclease Compliance
New enzyme derivatives are being welcomed across the biopharmaceuticals industry following easier red biotechnology applications, as illustrated by Dr Pablo Domínguez de María on behalf of c-LEcta and Dr Stefan Schoenert at c-LEcta.
|
|
|
|
RPA Development
Technique Transition
Dr Olaf Piepenburg at TwistDx explores the advantages of recombinase polymerase amplification, which is growing in popularity as an alternative to traditional polymerase chain reactions for testing outside the laboratory.
|
|
|
|
Tumour Heterogeneity
Alternative Approaches
Dr Ute Boronowsky at Oxford Genetics introduces a new gene editing tool that has been developed to iron out issues often encountered during single-cell analysis.
|
|
|
|
|
|
Diabetes Biosimilars
Calibrating Expectations
Rafal Kokolus, Dr Doug Niven, and Rohit Sood at Syneos Health claim that diabetes treatments could change following the increasing incorporation of biosimilars as an alternative therapeutic.
|
|
|
|
|
|
ADC Development
Targeted Treatment
Given the rise in usage of antibody-drug conjugates in cancer therapy, addressing the problems they
sometimes present is important. Edward Barnes, Dr David Bunka, and Dr Arron Tolley at Aptamer Group demonstrate how aptamers can help alleviate these.
|
|
|
|
Advancing ADC Technology
The Future of ADCs
Changed approaches and new technologies in the drugs’ development sector has given rise to improved and innovative targeted drugs, as explained byDr Neil Butt at IONTAS.
|
|
|
|
Targeted Therapies
Engineering Antibodies
Targeted antibodies are always evolving, though the challenges they often come with still remain. Professor Andreas Pahl at Heidelberg Pharma illustrates the ways in which these can be overcome.
|
|
|
|
|
|
